Charles River Laboratories International (CRL) Shares are Down -0.31%

Charles River Laboratories International (CRL) : During the past 4 weeks, traders have been relatively bearish on Charles River Laboratories International (CRL), hence the stock is down -5.11% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.28% relative to the S&P 500. The 4-week change in the price of the stock is -4.75% and the stock has fallen -0.31% in the past 1 week.

Charles River Laboratories International, Inc. has dropped 2.28% during the last 3-month period . Year-to-Date the stock performance stands at 2.82%. The stock has recorded a 20-day Moving Average of 3.22% and the 50-Day Moving Average is 2%.


Charles River Laboratories International (NYSE:CRL): The stock opened at $83.24 on Friday but the bulls could not build on the opening and the stock topped out at $83.39 for the day. The stock traded down to $82.38 during the day, due to lack of any buying support eventually closed down at $82.66 with a loss of -0.84% for the day. The stock had closed at $83.36 on the previous day. The total traded volume was 199,704 shares.

Also, Citigroup maintains its rating on Charles River Laboratories International (NYSE:CRL). The global brokerage major raises the current price target from $85 per share to $90 per share. Analysts at the Citigroup have a current rating of Neutral on the shares. The rating by the firm was issued on August 4, 2016.

Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.